Metastatic Non-Small Cell Lung Carcinoma

Oncology
0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Genomics
GenomicsUK - Oxford
1 program
Blood-based cell-free cfDNA qPCR assayN/A1 trial
Active Trials
NCT03892096Completed130Est. Feb 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
GenomicsBlood-based cell-free cfDNA qPCR assay

Clinical Trials (1)

Total enrollment: 130 patients across 1 trials

NCT03892096GenomicsBlood-based cell-free cfDNA qPCR assay

Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer

Start: Mar 2019Est. completion: Feb 2024130 patients
N/ACompleted

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space